Ionis Pharmaceuticals (IONS) and Its Competitors Head to Head Contrast

Ionis Pharmaceuticals (NASDAQ: IONS) is one of 185 public companies in the “Biotechnology & Medical Research” industry, but how does it compare to its peers? We will compare Ionis Pharmaceuticals to similar businesses based on the strength of its institutional ownership, risk, earnings, valuation, dividends, analyst recommendations and profitability.

Earnings and Valuation

This table compares Ionis Pharmaceuticals and its peers revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Ionis Pharmaceuticals $346.62 million -$86.55 million 353.96
Ionis Pharmaceuticals Competitors $217.29 million -$39.39 million -73.31

Ionis Pharmaceuticals has higher revenue, but lower earnings than its peers. Ionis Pharmaceuticals is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Analyst Ratings

This is a breakdown of current ratings for Ionis Pharmaceuticals and its peers, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Ionis Pharmaceuticals 2 6 6 0 2.29
Ionis Pharmaceuticals Competitors 527 2397 6577 123 2.65

Ionis Pharmaceuticals presently has a consensus price target of $50.38, indicating a potential downside of 5.10%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 15.06%. Given Ionis Pharmaceuticals’ peers stronger consensus rating and higher probable upside, analysts clearly believe Ionis Pharmaceuticals has less favorable growth aspects than its peers.


This table compares Ionis Pharmaceuticals and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Ionis Pharmaceuticals 3.46% 7.50% 1.58%
Ionis Pharmaceuticals Competitors -3,346.36% -537.76% -40.12%

Institutional & Insider Ownership

91.6% of Ionis Pharmaceuticals shares are owned by institutional investors. Comparatively, 49.8% of shares of all “Biotechnology & Medical Research” companies are owned by institutional investors. 2.1% of Ionis Pharmaceuticals shares are owned by insiders. Comparatively, 14.7% of shares of all “Biotechnology & Medical Research” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Volatility & Risk

Ionis Pharmaceuticals has a beta of 2.85, suggesting that its share price is 185% more volatile than the S&P 500. Comparatively, Ionis Pharmaceuticals’ peers have a beta of 1.57, suggesting that their average share price is 57% more volatile than the S&P 500.


Ionis Pharmaceuticals beats its peers on 7 of the 13 factors compared.

Ionis Pharmaceuticals Company Profile

Ionis Pharmaceuticals, Inc. is engaged in discovering and developing ribonucleic acid (RNA)-targeted therapeutics. The Company, using its drug discovery platform, has developed a pipeline of drugs for patients with unmet medical needs. The Company’s segments include Ionis Core and Akcea Therapeutics. In the Ionis Core segment, the Company is engaged in exploiting a drug discovery platform to generate a pipeline of drugs for the Company and its partners. The Akcea Therapeutics segment includes the operations of the Company’s subsidiary, Akcea Therapeutics, Inc. (Akcea Therapeutics). Akcea Therapeutics is focused on developing and commercializing volanesorsen and other clinical-stage drugs for serious cardiometabolic diseases caused by lipid disorders. The Company is developing volanesorsen to treat two severe and rare, genetically defined diseases, familial chylomicronemia (FCS) and familial partial lipodystrophy (FPL). The Company offers SPINRAZA, a Generation 2.0+ antisense drug.

Receive News & Ratings for Ionis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals Inc. and related companies with's FREE daily email newsletter.

Leave a Reply